Cognivue, Inc.

Article published last month in Scientific Reports demonstrates Cognivue Clarity’s ability to reliably differentiate between the cognitively normal, mild cognitive impairment (MCI), and mild dementia groups regardless of amyloid status. Main Takeaways: ➡️ Cognivue Clarity reliably detected cognitive impairment in clinical and biomarker-confirmed samples. ➡️ Cognivue Clarity differentiated between cognitively normal, MCI, and dementia groups regardless of amyloid status. ➡️ With support of statistically significant findings—Cognivue Clarity captured most individuals with cognitive impairment, and excluded most individuals who are cognitively normal—Cognivue Clarity can provide useful information for consideration for further evaluation with biomarkers and detailed neuropsychological evaluation. ➡️ Cognivue Clarity’s ability to differentiate MCI due to AD from AD, and between AD and non-AD forms of impairment has value to clinical research and real-world practice as AD treatments move to a more precision-based approach where differential treatment options (pharmacologic and non-pharmacologic) may require such distinction. Read it here: https://lnkd.in/eddUPM8z Data comes from the Bio-Hermes study, sponsored by the Global Alzheimer's Platform Foundation. #alzheimersdisease #amyloid #mildcognitiveimpairment #dementia #cognitivehealth #biohermes #earlydetection #cognivue Cognivue, Inc.

When asked about how he hopes the Bio-Heremes-002 study will impact the future, Dr. Ernest Fung, PsyD, ABPP-CN, Senior Vice President of Clinical and Medical Affairs at Cognivue, Inc. had the following to share: “I think what is really going to be important, this study is going to provide valuable data that I believe will streamline future diagnostic and assessment process. And together, with data coming from a diverse subject group, I think it will help us to make dementia diagnosis more accessible—not just from a practical standpoint, but from a financial standpoint—serving to increase health equity for different populations.” Cognivue recently announced a strategic partnership with the Global Alzheimer's Platform Foundation (GAP) as we participate in the Bio-Hermes-002 clinical trial study with the Congivue Clarity device. Cognivue Clarity is a non-invasive and repeatable digital cognitive assessment tool that can assess cognitive functioning and amyloid presence effectively and efficiently in 10 minutes. #BioHermes002 #BioHermes #StopALZ #Alzheimersdisease #cognitiveassessment #accessibility #digitalbiomarker #cognivue

Based on data from the Bio-Hermes-001 study, Cognivue, Inc. developed a new metric, the Cognivue Amyloid Risk Measure (CARM). We presented a poster on this last week at the CTAD Clinical Trials on Alzheimer's Disease conference to show that the CARM metric—derived from a portion of the current Cognivue Clarity assessment—can predict the presence of amyloid in individuals with or without cognitive impairment. The CARM score is a novel method of detecting the presence of amyloid which may: ➡️ Provide additional support on Cognivue Clarity’s ability to characterize the likelihood of: 🧠 Cognitive impairment—regardless of amyloid positivity 🧠 AD etiology—regardless of cognitive status ➡️ Help identify individuals with and without cognitive impairment due to AD or non-AD etiologies Learn More: https://bit.ly/4fAn1nf #alzheimersdisease #alzheimers #amyloid #cognitiveassessment #earlydetection #biohermes #cognivue Global Alzheimer's Platform Foundation

Cognivue, Inc. is thrilled to be part of the Bio-Hermes-002 study! We’re excited about the results that will come from the study and how they will elevate the standard of care for Alzheimer’s disease. #BioHeremes002 #brainhealth #StopAlz #alzheimersdisease #dementia

Wrapping up the 2024 CTAD Clinical Trials on Alzheimer's Disease Conference in Madrid and heading back to the States. There are so many changes happening in the dementia space, and this conference was full of some of the really important discussions taking place around Alzheimer's disease clinical research. We look forward to seeing how outputs from CTAD 2024 will shape Alzheimer's research to come. Cognivue, Inc. presented a poster at CTAD on our scientific findings that illustrate a novel method that predicts the presence of amyloid. More to be shared in a future post about the poster, titled “The Cognivue Amyloid Risk Measure (CARM): A Novel Method to Detect the Presence of Amyloid in Clinical Samples with Cognivue Clarity®.” Since inception, Cognivue has invested in developing its cognitive assessment platform to advance technologies used in screening for Alzheimer’s disease and other related dementias. Email events@cognivue.com to learn more about our platform. #CTAD24 #alzheimersdisease #alzheimers #amyloid #cognitiveassessment #earlydetection #cognivue

Live today in Madrid, Spain! Poster presentation for # P184 is taking place at the CTAD Clinical Trials on Alzheimer's Disease 2024 Conference. We look forward to presenting Cognivue, Inc.'s scientific findings that illustrate a novel method that predicts the presence of amyloid. Poster Title: “The Cognivue Amyloid Risk Measure (CARM): A Novel Method to Detect the Presence of Amyloid in Clinical Samples with Cognivue Clarity®.” Poster Authors: James Galvin; Michael J Kleiman; Paul W. Estes; HEATHER M. HARRIS; and Ernest Fung, PsyD, ABPP-CN. Data comes from the Bio-Hermes study, sponsored by the Global Alzheimer's Platform Foundation. #CTAD24 #earlydetection #alzheimersdisease #AD #preclinical #cognitivehealth #cognitive screening #DCA #cognivue

Cognivue, Inc. announces a strategic partnership with the Global Alzheimer's Platform Foundation (GAP) as we participate in the Bio-Hermes-002 clinical trial study. “The work Cognivue did with GAP as part of the Bio-Hermes-001 study was meaningful. Our technology was in good company; it was an honor to be amongst other esteemed digital and plasma biomarkers in a study with a racially diverse cohort. The data from BH1 showed that Cognivue Clarity can reliably characterize amyloid status, even within the cognitively normal group. Our participation in BH2 will allow us to continue to gather data to support Cognivue Clarity’s ability to predict underlying AD pathologies and analyze MRI, neuroinflammation and longitudinal data—further establishing Cognivue’s important role in the timely assessment and diagnosis of dementia and enrichment of clinical trial recruitment,” said Paul W. Estes, president of Cognivue. “We look forward to working with our friends at GAP and the trial sites again.” Read about it here: https://bit.ly/40qigIA #BioHermes002 #StopALZ #Alzheimersdisease #cognitiveassessment #digitalbiomarker #cognivue

We are excited to announce Cognivue, Inc.'s latest publication in the Scientific Reports journal. This peer-reviewed article demonstrates Cognivue Clarity’s ability to reliably differentiate between the cognitively normal, MCI, and mild dementia groups regardless of amyloid status. Therefore, it can provide useful information for consideration for further evaluation with biomarkers and more detailed neuropsychological evaluation in both clinical research and clinical practice settings. The data comes from the Bio-Hermes study, sponsored by the Global Alzheimer's Platform Foundation. Read it here: https://lnkd.in/erdydUjP Cognivue Clarity is a non-invasive and repeatable digital cognitive assessment tool that can assess cognitive functioning and amyloid presence effectively and efficiently in 10 minutes. #alzheimersdisease #AD #amyloid #normal #mildcognitiveimpairment #milddementia #dca #assessment #cognitivehealth #biohermes #earlydetection #cognivue

Cognivue, Inc. will be attending the 17th CTAD Clinical Trials on Alzheimer's Disease Conference taking place October 29th-November 1st, 2024. To set up a meeting with one of our representatives, contact events@cognivue.com. Don’t miss our poster presentation # P184 on November 1st. Building on the robust findings that show Cognivue Clarity’s ability to effectively 1) distinguish between cognitively normal, MCI and mild dementia (regardless of amyloid status) and 2) characterize preclinical AD in about 10 minutes, we look forward to presenting additional data illustrating a novel method that predicts the presence of amyloid. Learn more about Cognivue Clarity—a digital cognitive assessment tool that can assess cognitive functioning and amyloid presence effectively and efficiently. #CTAD24 #earlydetection #alzheimersdisease #AD #preclinical #cognitivehealth #cognitivescreening #DCA #clinicaltrial #reasearch #cognivue

Brought to you by AuDExperts, “Practice Growth and Personal Freedom” is a 2-day event taking place next week in Las Vegas, NV on October 25-26th. This is a great opportunity (with a full agenda) to learn best practice techniques other Hearing Healthcare private practice owners are using to be successful. Register Here: https://bit.ly/3BZKj7x Cognivue, Inc. is proud to be a sponsor of this event which aligns closely with our mission to advance early detection of cognitive impairment in order to address modifiable risk factors sooner (Hearing Loss is a #1 modifiable risk factor). Jared Brader, MBA Dr. Keith Darrow, PhD, CCC-A #hearingandcognition #hearinghealthcare #audiology #cognitivehealth #cognitivescreening #modifiableriskfactors #reducerisk #earlydetection #bestpractice #cognivue